Merck Animal Health shared earlier this week that the FDA approved its atinvicitinib tablets (NUMELVI; Merck Animal Health), a once daily, first line treatment for canine patients 6 months and older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results